Simultaneous Quantification of Free and Glucuronidated Cannabinoids in Human Urine by Liquid Chromatography Tandem Mass Spectrometry

Overview

Journal Clin Chim Acta

Specialty Biochemistry

Date 2012 Jul 10

PMID 22771478

Citations 17

Authors

Karl B Scheidweiler

Nathalie A Desrosiers

Marilyn A Huestis

Affiliations

Soon will be listed here.

Abstract

Background: Cannabis is the most commonly abused drug of abuse and is commonly quantified during urine drug testing. We are conducting a controlled drug administration study investigating efficacy of urinary cannabinoid glucuronide metabolites for documenting recency of cannabis intake and for determining stability of urinary cannabinoids.

Methods: A liquid chromatography tandem mass spectrometry method was developed and validated quantifying Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), 11-nor-9-carboxy-THC (THCCOOH), cannabidiol, cannabinol, THC-glucuronide and THCCOOH-glucuronide in 0.5 ml human urine via supported-liquid extraction. Chromatography was performed on an Ultra Biphenyl column with a gradient of 10 mmol/l ammonium acetate, pH 6.15 and 15% methanol in acetonitrile at 0.4 ml/min. Analytes were monitored by positive and negative mode electrospray ionization and multiple reaction monitoring mass spectrometry.

Results: Linear ranges were 0.5-50 ng/ml for THC-glucuronide, 1-100 ng/ml for THCCOOH, 11-OH-THC and cannabidiol, 2-100 ng/ml for THC and cannabinol, and 5-500 ng/ml for THCCOOH-glucuronide (R(2)>0.99). Mean extraction efficiencies were 34-73% with analytical recovery (bias) 80.5-118.0% and total imprecision 3.0-10.2% coefficient of variation.

Conclusion: This method simultaneously quantifies urinary cannabinoids and phase II glucuronide metabolites, and enables evaluation of urinary cannabinoid glucuronides for documenting recency of cannabis intake and cannabinoid stability. The assay is applicable for routine urine cannabinoid testing.

Citing Articles

Investigation of commercially available recombinant and conventional β-glucuronidases to evaluate the hydrolysis efficiencies against O-glucuronides and N-glucuronides in urinary drug screening.

Namera A, Saito T, Nagao M Forensic Toxicol. 2025; .

PMID: 40042693 DOI: 10.1007/s11419-025-00715-6.

Quantitative analysis of Δ- and Δ-tetrahydrocannabinol metabolites and isomers: a rapid assay in urine by LC-MS/MS.

Ballotari M, Truver M, Sojin N, Agliano L, Parimoo R, Hoyer J Anal Bioanal Chem. 2025; 417(8):1507-1518.

PMID: 39847096 DOI: 10.1007/s00216-025-05738-x.

Enhancement and validation of a quantitative GC-MS method for the detection of ∆9-THC and THC-COOH in postmortem blood and urine samples.

Paknahad S, Jokar F, Koohi M, Ghadipasha M, Hassan J, Akhgari M MethodsX. 2024; 13:102962.

PMID: 39415877 PMC: 11480513. DOI: 10.1016/j.mex.2024.102962.

An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis.

Bawa Z, Lewis D, Gavin P, Libinaki R, Joubran L, El-Tamimy M Sci Rep. 2024; 14(1):11792.

PMID: 38783008 PMC: 11116491. DOI: 10.1038/s41598-024-62428-x.

Simultaneous quantification of urinary tobacco and marijuana metabolites using solid-supported liquid-liquid extraction coupled with liquid chromatography tandem mass spectrometry.

Yakimavets V, Qiu T, Panuwet P, DSouza P, Brennan P, Dunlop A J Chromatogr B Analyt Technol Biomed Life Sci. 2022; 1208:123378.

PMID: 35908438 PMC: 10317196. DOI: 10.1016/j.jchromb.2022.123378.

References

Huestis M . Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2006; (168):657-90. DOI: 10.1007/3-540-26573-2_23. View

Wall M, Sadler B, Brine D, Taylor H, PEREZ-REYES M . Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983; 34(3):352-63. DOI: 10.1038/clpt.1983.179. View

Smith M, Barnes A, Huestis M . Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol. 2009; 33(4):185-9. PMC: 3159564. DOI: 10.1093/jat/33.4.185. View

Crockett D, Nelson G, Dimson P, Urry F . Solid-phase extraction of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid from urine drug-testing specimens with the cerex polycrom-THC column. J Anal Toxicol. 2000; 24(4):245-9. DOI: 10.1093/jat/24.4.245. View

Shipkova M, Armstrong V, Oellerich M, Wieland E . Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003; 25(1):1-16. DOI: 10.1097/00007691-200302000-00001. View

Williams P, Moffat A . Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol. 1980; 32(7):445-8. DOI: 10.1111/j.2042-7158.1980.tb12966.x. View

Christophersen A . Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol. 1986; 10(4):129-31. DOI: 10.1093/jat/10.4.129. View

Lowe R, Abraham T, Darwin W, Herning R, Cadet J, Huestis M . Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009; 105(1-2):24-32. PMC: 2763020. DOI: 10.1016/j.drugalcdep.2009.05.027. View

Skopp G, Potsch L . An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol. 2004; 28(1):35-40. DOI: 10.1093/jat/28.1.35. View

10.

Singh J, Johnson L . Solid-phase extraction of THC metabolite from urine using the Empore disk cartridge prior to analysis by GC-MS. J Anal Toxicol. 1997; 21(5):384-7. DOI: 10.1093/jat/21.5.384. View

11.

Karschner E, Schwilke E, Lowe R, Darwin W, Pope H, Herning R . Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. Addiction. 2009; 104(12):2041-8. PMC: 2784185. DOI: 10.1111/j.1360-0443.2009.02705.x. View

12.

Feng S, ElSohly M, Salamone S, Salem M . Simultaneous analysis of delta9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure. J Anal Toxicol. 2000; 24(6):395-402. DOI: 10.1093/jat/24.6.395. View

13.

Mareck U, Haenelt N, Geyer H, Guddat S, Kamber M, Brenneisen R . Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal. 2010; 1(11-12):505-10. DOI: 10.1002/dta.106. View

14.

Felli M, Martello S, Chiarotti M . LC-MS-MS method for simultaneous determination of THCCOOH and THCCOOH-glucuronide in urine: Application to workplace confirmation tests. Forensic Sci Int. 2010; 204(1-3):67-73. DOI: 10.1016/j.forsciint.2010.05.004. View

15.

Skopp G, Potsch L . Stability of 11-nor-delta(9)-carboxy-tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem. 2002; 48(2):301-6. View

16.

Schwope D, Scheidweiler K, Huestis M . Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011; 401(4):1273-83. PMC: 3159033. DOI: 10.1007/s00216-011-5197-7. View

17.

Abraham T, Lowe R, Pirnay S, Darwin W, Huestis M . Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol. 2007; 31(8):477-85. PMC: 2689549. DOI: 10.1093/jat/31.8.477. View

18.

Grauwiler S, Scholer A, Drewe J . Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850(1-2):515-22. DOI: 10.1016/j.jchromb.2006.12.045. View

19.

Moon J, Kim J, Moon M, Chung B, In M, Choi M . Validated gas chromatographic-mass spectrometric analysis of urinary cannabinoids purified with a calcium-hardened beta-cyclodextrin polymer. J Chromatogr A. 2008; 1204(1):87-92. DOI: 10.1016/j.chroma.2008.07.083. View

20.

Schwope D, Karschner E, Gorelick D, Huestis M . Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem. 2011; 57(10):1406-14. PMC: 3717336. DOI: 10.1373/clinchem.2011.171777. View